CY 09

Key Product Details

Product Description

CY 09 is a NLRP3 inhibitor (K_d = 500 nM); directly binds to ATP-binding motif of NLRP3 NACHT domain. Blocks NLRP3 inflammasome assembly and activation. Displays therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes. Exhibits no activity for hERG (10 μM).

Product Specifications for CY 09

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CY 09

The following data is based on the product molecular weight 423.43.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	11.81 mL	59.04 mL	118.08 mL
1 mM	2.36 mL	11.81 mL	23.62 mL
2 mM	1.18 mL	5.90 mL	11.81 mL
10 mM	0.24 mL	1.18 mL	2.36 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Jiang Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J.Exp.Med. 2017 PMID: 29021150

Product Documents for CY 09